Top

International Journal of Clinical Oncology

Published in:

01-02-2013 | Original Article

Carboplatin–gemcitabine combination chemotherapy upregulates AKR1B10 expression in bladder cancer

Authors: Yasuhiro Hashimoto, Kengo Imanishi, Noriko Tokui, Teppei Okamoto, Akiko Okamoto, Shingo Hatakeyama, Takahiro Yoneyama, Takuya Koie, Noritaka Kamimura, Chikara Ohyama

Published in: International Journal of Clinical Oncology | Issue 1/2013

Abstract

Background

AKR1B10 is considered to contribute to cell proliferation and chemoresistance. In the present study, we examined whether AKR1B10 expression is associated with disease-free survival in bladder cancer patients.

Methods

We obtained bladder cancer specimens from 10 patients before and after chemotherapy and measured AKR1B10 mRNA levels using real-time PCR. In addition, we conducted an immunohistochemical examination of AKR1B10 expression in 57 patients with bladder cancer before and after chemotherapy.

Results

AKR1B10 mRNA expression was significantly higher in the post-chemotherapy group than in the pre-chemotherapy group (p < 0.001). The average immunohistochemical intensity score in the pre-chemotherapy group was 0.83 ± 1.08, compared with the significantly higher score of 2.03 ± 1.03 in the post-chemotherapy group (p < 0.001). The disease-free survival rate of post-chemotherapy AKR1B10(+) patients (61.2%) was significantly lower than that of AKR1B10(−) patients (100%) (log-rank test, p = 0.039).

Conclusions

Although the present study is small and preliminary, our data suggest that post-chemotherapy AKR1B10 expression may be associated with a poor prognosis in patients who received carboplatin–gemcitabine combination chemotherapy and underwent cystectomy. Further study is warranted to elucidate its clinical significance.

Penning TM (2005) AKR1B10: a new diagnostic marker of non-small cell lung carcinoma in smokers. Clin Cancer Res 11:1687–1690PubMedCrossRef

Kasajima H, Yamagishi S, Sugai S et al (2001) Enhanced in situ expression of aldose reductase in peripheral nerve and renal glomeruli in diabetic patients. Virchows Arch 439:46–54PubMedCrossRef

Oates PJ (2010) Aldose reductase inhibitors and diabetic kidney disease. Curr Opin Investig Drugs 11:402–417PubMed

Hwang YC, Kaneko M, Bakr S et al (2004) Central role for aldose reductase pathway in myocardial ischemic injury. FASEB J 18:1192–1199PubMedCrossRef

Yagihashi S, Mizukami H, Ogasawara S et al (2010) The role of the polyol pathway in acute kidney injury caused by hindlimb ischaemia in mice. J Pathol 220:530–541PubMedCrossRef

Cao D, Fan ST, Chung SS (1998) Identification and characterization of a novel human aldose reductase-like gene. J Biol Chem 273:11429–11435PubMedCrossRef

Fukumoto S, Yamauchi N, Moriguchi H et al (2005) Overexpression of the aldo-keto reductase family protein akr1b10 is highly correlated with smokers’ non-small cell lung carcinomas. Clin Cancer Res 11:1776–1785PubMedCrossRef

Yoshitake H, Takahashi M, Ishikawa H et al (2007) Aldo-keto reductase family 1, member b10 in uterine carcinomas: a potential risk factor of recurrence after surgical therapy in cervical cancer. Int J Gynecol Cancer 17:1300–1306PubMedCrossRef

Heringlake S, Hofdmann M, Fiebeler A et al (2010) Identification and expression analysis of the aldo-ketoreductase1-B10 gene in primary malignant liver tumours. J Hepatol 52:220–227PubMedCrossRef

10.

Wang C, Yan R, Luo D et al (2009) Aldo-keto reductase family 1 member B10 promotes cell survival by regulating lipid synthesis and eliminating carbonyls. J Biol Chem 284:26742–26748PubMedCrossRef

11.

Martin HJ, Breyer-Pfaff U, Wsol V et al (2006) Purification and characterization of akr1b10 from human liver: role in carbonyl reduction of xenobiotics. Drug Metab Dispos 34:464–470PubMedCrossRef

12.

Koie T, Yamamoto H, Okamoto A et al (2009) Feasibility and efficacy of gemcitabine and carboplatin neoadjuvant chemotherapy in muscle-invasive bladder cancer. J Clin Oncol 27(suppl):e16100

13.

Calvert AH, Newell DR, Gumbrell LA et al (1989) Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7:1748–1756PubMed

14.

Langer S, Kokozidou M, Heiss C et al (2010) Chronic kidney disease aggravates arteriovenous fistula damage in rats. Kidney Int 78:1312–1321PubMedCrossRef

15.

Takahashi M, Hoshi A, Fujii J et al (1996) Induction of aldose reductase gene expression in LEC rats during the development of the hereditary hepatitis and hepatoma. Jpn J Cancer Res 87:337–341PubMedCrossRef

16.

Zeindl-Eberhart E, Jungblut PR, Otto A et al (1997) Further characterization of a rat hepatoma-derived aldose-reductase-like protein—organ distribution and modulation in vitro. Eur J Biochem 247:792–800PubMedCrossRef

17.

Baris D, Karagas MR, Verrill C et al (2009) A case–control study of smoking and bladder cancer risk: emergent patterns over time. J Natl Cancer Inst 101:1553–1561PubMedCrossRef

18.

Kurahashi N, Inoue M, Iwasaki M et al (2009) Coffee, green tea, and caffeine consumption and subsequent risk of bladder cancer in relation to smoking status: a prospective study in Japan. Cancer Sci 100(2):294–391PubMedCrossRef

19.

Yan R, Zu X, Ma J et al (2007) Aldo-keto reductase family 1 B10 gene silencing results in growth inhibition of colorectal cancer cells: implication for cancer intervention. Int J Cancer 121:2301–2306PubMedCrossRef

Title: Carboplatin–gemcitabine combination chemotherapy upregulates AKR1B10 expression in bladder cancer
Authors: Yasuhiro Hashimoto
Kengo Imanishi
Noriko Tokui
Teppei Okamoto
Akiko Okamoto
Shingo Hatakeyama
Takahiro Yoneyama
Takuya Koie
Noritaka Kamimura
Chikara Ohyama
Publication date: 01-02-2013
Publisher: Springer Japan
Published in: International Journal of Clinical Oncology / Issue 1/2013
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-011-0363-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2013

Enhanced antitumor effect of lower-dose and longer-term CPT-11 treatment in combination with low-dose celecoxib against neuroblastoma xenografts

Factors associated with the survival of patients with primary small cell carcinoma of the kidney

Computed tomography fluoroscopy-guided radiofrequency ablation following intra-arterial iodized-oil injection for hepatocellular carcinomas invisible on ultrasonographic images

Neoadjuvant and adjuvant chemotherapy with modified mesna, adriamycin, ifosfamide, and dacarbazine (MAID) regimen for adult high-grade non-small round cell soft tissue sarcomas

Transurethral prostate biopsy before radical cystectomy remains clinically relevant for decision-making on urethrectomy in patients with bladder cancer

Can docetaxel therapy improve overall survival from primary therapy compared with androgen-deprivation therapy alone in Japanese patients with castration-resistant prostate cancer? A multi-institutional cooperative study

Keynote webinar | Spotlight on antibody–drug conjugates in cancer